What's new? Log in Free sign up

Invivyd (IVVD) News and press releases

Company Profile

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design.

Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.

HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $5 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Patrick Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $5 price target.

Invivyd: Q1 Earnings Insights

Invivyd Q1 EPS $(0.32) Misses $(0.30) Estimate

Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 65.59 percent increase over losses of $(0.93) per share from the same

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.

Earnings Preview: Invivyd

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

HC Wainwright & Co. Initiates Coverage On Invivyd with Buy Rating, Announces Price Target of $5

News, Price Target, Initiation, Analyst Ratings

HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Invivyd (NASDAQ:IVVD) with a Buy rating and announces Price Target of $5.

The FDA Has Cleared Invivyd's Investigational New Drug Application For VYD222, A Monoclonal Antibody Candidate To Prevent COVID-19 In Vulnerable Populations

Biotech, News, Health Care, FDA, General

As previously announced, VYD222 is currently being evaluated in an ongoing Phase 1 healthy volunteer clinical trial being conducted in Australia.

Morgan Stanley Maintains Underweight on Invivyd, Lowers Price Target to $1

News, Price Target, Analyst Ratings

Morgan Stanley analyst Matthew Harrison maintains Invivyd (NASDAQ:IVVD) with a Underweight and lowers the price target from $2 to $1.

Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50.

Stocks That Hit 52-Week Lows On Friday

On Friday, 469 companies hit new 52-week lows.

Earnings Scheduled For March 23, 2023

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.

Invivyd Earnings Preview

Invivyd Elects VYD222 To Advance Into The Clinic As A Novel Monoclonal Antibody Therapeutic Option For COVID-19

Biotech, News, Health Care, General

The company said as of January 2023, there are no monoclonal antibodies authorized or approved in the U.S. for the prevention or treatment of COVID-19. Monoclonal antibodies are well suited to meet the need of

Press releases

From Benzinga Pro

INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Invivyd, Inc. (NASDAQ:IVVD) on behalf of long-term stockholders following a class action

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

Earnings, Press Releases

Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data readouts from Phase 1

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

News, Press Releases

WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced

Invivyd to Participate at H.C. Wainwright's BioConnect Investor Conference

News, Press Releases

WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

News, Management, Press Releases

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced

DEADLINE ALERT for ALIZY, IVVD, and RVYL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

News, Legal, Press Releases

LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors of Class Action and Last Few Hours to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or the "Company") (NASDAQ:IVVD)

Invivyd Class Action: Levi & Korsinsky Reminds Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 3, 2023 - IVVD

New York, New York--(Newsfile Corp. - April 3, 2023) - Levi & Korsinsky, LLP notifies investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or the "Company") (NASDAQ:IVVD) of a class action securities

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - April 3, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio Therapeutics,

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGI

NEW YORK, April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) ("Adagio" or the "Company") (NASDAQ: IVVD; ADGI).

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Invivyd Investors of a Lead Plaintiff Deadline of April 3, 2023

NEW YORK, April 3, 2023 /PRNewswire/ -- Attention Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd") (NASDAQ:IVVD) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has

Invivyd Shareholder Action Reminder

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Invivyd To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 2,

IVVD DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI

New York, New York--(Newsfile Corp. - April 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ:IVVD)

INVIVYD DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Invivyd, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Invivyd, Inc. ("Invivyd" or the "Company") (NASDAQ:IVVD) in the

INVIVYD 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 3, 2023 to file lead plaintiff applications in a

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD)

Penny Stocks, Press Releases

The Law Offices of Frank R.

IVVD Investors Have Opportunity to Lead Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Securities Fraud Lawsuit

Penny Stocks, Press Releases

LOS ANGELES, March 31, 2023 /PRNewswire/ --

DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - March 31, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio

IVVD SHAREHOLDER ALERT: Jakubowitz Law Reminds Invivyd Shareholders of a Lead Plaintiff Deadline of April 3, 2023

NEW YORK, March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ:IVVD). To

IVVD FINAL DEADLINE MONDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI

News, Legal, Press Releases

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ:IVVD, ADGI)) between

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.